Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial

Table 1 Chemotherapy regimens for NSCLC

Pathologic types	Chemotherapy regimen	Dosage (mg/m²)	Medication time
Squamous cell carcinoma	GC
	Gemcitabine	1000	D1, 8
	Cisplatinum	75	D1–3
	GC
	Gemcitabine	1000	D1, 8
	Carboplatin	AUC = 6	D1
Adenocarcinoma, large cell, NSCLC not otherwise specified (NOS)	PP
	Pemetrexed	500	D1
	Cisplatinum	75	D1–3
	PC
	Pemetrexed	500	D1
	Carboplatin	AUC = 6	D1

Notes: If patients experience gemcitabine-associated intolerable toxicities, paclitaxel will be used instead of gemcitabine. The dose of paclitaxel is 135 mg/m² D1. The dosages of the chemotherapy regimens are provided only for reference, and specific implementation will take clinical application as a standard
AUC area under the curve, NSCLC non-small cell lung cancer

ISSN: 1745-6215